Brought to you by 
Qiagen helps develop a companion test for Clovis Oncology's EGFR inhibitor candidate
04 Nov 2013
Executive Summary
Assay developer Qiagen NV has agreed to design a new companion diagnostic for Clovis Oncology Inc. (cancer therapies and tests) that will help identify the T790M resistance mutation in patients with epidermal growth factor receptor (EGFR) driven non-small cell lung cancer who have been heavily pre-treated with EGFR-inhibiting drugs.
Deal Industry
- In Vitro Diagnostics
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Qiagen helps develop a companion test for Clovis Oncology's EGFR inhibitor candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice